Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine
Reference42 articles.
1. Update in global trends and aetiology of hepatocellular carcinoma;Rawla;Contemp. Oncol.,2018
2. The global epidemiology of hepatocellular carcinoma: present and future;McGlynn;Clin. Liver Dis.,2011
3. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang;Nat. Rev. Gastroenterol. Hepatol.,2019
4. Mechanisms of resistance to chemotherapy and radiotherapy in hepatocellular carcinoma;Guo;Transl. Cancer Res.,2018
5. Prognosis of untreated hepatocellular carcinoma;Giannini;Hepatology,2015
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient;Cancer Gene Therapy;2024-07-27
2. Exploring treatment options in cancer: tumor treatment strategies;Signal Transduction and Targeted Therapy;2024-07-17
3. Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner;Biomarker Research;2024-03-25
4. Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer;Journal of Translational Medicine;2024-01-02
5. Regulation of telomerase towards tumor therapy;Cell & Bioscience;2023-12-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3